Headlines

Chris Lewis

Chris Lewis is Tech Insider's Senior Equity Research analyst covering Internet and Interactive Entertainment. Prior to joining TI in 2011, Chris spent six years at Baird Capital having established the company’s Internet and Video Game research practice. Prior to Wall Street, Chris was a business analyst developing software at Chubb Corporation, and was a co-founder and CFO of Latin American career services website Detacuche.com. Chris appears frequently in the financial and industry press, including CNBC, Bloomberg, CNN, Wall Street Journal, and Financial Times, among others.

Gilead Sciences GILD NASDAQ:GILD

Market Movers Roundup: Trina Solar Limited (NYSE: TSL), Deere & Company (NYSE: DE), Tower Semiconductor Ltd. (NASDAQ:TSEM), Kohl’s (NYSE: KSS)

Chris Lewis02 mins

American Depositary Receipts of Trina Solar Limited (NYSE: TSL) are up 0.1% in the pre-market session, as the solar-power products manufacturer reports a new EPC contract with Fresh Fruits Company, a food storage and logistics company in Amman, Jordan. TSL has been awarded the contract that calls for engineering, procurement, and construction services for a…

Read More

Morning Buzz: SODA, SUSS, RL, CDI

Chris Lewis03 mins

Sodastream International (NASDAQ: SODA) was volatile in pre-market trade after reporting Q4 earnings that fell less than expected and as the FY sales guidance was short of analysts’ estimates. Having earlier trading higher by as much as 3% in pre-market trade, the stock was recently down 0.2% at $39.00. The maker of home beverage carbonation…

Read More

Trader’s Alert – Dyax Corp, Boeing, Tyco

Chris Lewis02 mins

Dyax Corp (NASDAQ:DYAX) shares rose 8.1% to $10.99, their highest price since mid-2004, after positive Phase 1a study results of DX-2930, a treatment for hereditary angioedema attacks. The first-in-human clinical study of DX-2930 met all objectives of assessing safety, tolerability and pharmacokinetics and showed it well tolerated at all dose levels. Pharmacokinetic results demonstrated that…

Read More
Home